Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib
复制标题
DOI：
10.3390/app10165403
复制
发表时间：
2020-08-01
影响因子：
2.7
通讯作者：
Sakaida, Isao
中科院分区：
文献类型：
--
作者：
Kotoh, Yurika;Saeki, Issei;Sakaida, Isao
以前的研究已经报道了肝细胞癌患者接受Lenvatinib治疗的预后因素；然而，还没有研究评估握力和骨骼肌块对临床结果的影响。因此，这项回顾性研究调查了53例接受Lenvatinib治疗的肝癌患者的握力、骨骼肌质量和肌肉量减少对临床结果的个体影响。在接受Lenvatinib治疗前，测量握力和骨骼肌指数。低握力和肌肉衰竭被定义为
Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore, this retrospective study investigated the individual effect of handgrip strength, skeletal muscle mass, and sarcopenia on clinical outcomes of 53 HCC patients treated with lenvatinib. Before receiving lenvatinib, handgrip strength and skeletal muscle index (SMI) were measured. Low handgrip strength and muscle depletion were defined as